LLY Eli Lilly and Company - Fundamental Analysis
BULLISH
LLY Stock | Fundamental Analysis & Investment Insights
NYSE
•
Healthcare
•
Drug Manufacturers - General
Current Price
$1025.28
Analyst Target
$1003.15
-2.2% Downside
52W High
$1033.62
52W Low
$623.78
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Nov 16, 2025
Market cap
$919.12B
P/E
50.26
ROE
96.5%
Profit margin
31.0%
Debt/Equity
1.79
Dividend yield
0.59%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
LLY shows bullish fundamentals based on available metrics. Key strengths include strong valuation and growth metrics.
Key Strengths
Strong profitability with 31.0% profit margin
Strong revenue growth of 53.9%
Strong ROE of 96.5%
Key Risks
High valuation with P/E of 50.3
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
55
Moderate
20
80
75
60
40
AI Verdict
LLY shows bullish fundamentals based on available metrics. Key strengths include strong valuation and growth metrics.
Key drivers: Strong profitability with 31.0% profit margin, Strong revenue growth of 53.9%, High valuation with P/E of 50.3
Confidence
75%
Value
20/100
Rule-based valuation fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- Premium 50.3x trailing earnings multiple.
- P/B of 38.6 signals rich expectations.
Future
80/100
Rule-based growth outlook.
Positives
- Revenue growth running at 53.9%.
- Earnings expanding at 480.4%.
Watchpoints
No urgent risks highlighted.
Past
75/100
Historical performance + price trend: Shares moved +668.5% over 5Y and +31.6% over 1Y.
Positives
- ROE sits at 96.5%.
- Healthy profit margin of 31.0%.
Watchpoints
No urgent risks highlighted.
Health
60/100
Balance sheet & liquidity snapshot.
Positives
- Current ratio 1.5 supports liquidity.
Watchpoints
No urgent risks highlighted.
Dividend
40/100
Dividend policy fallback.
Positives
- Pays dividend with 0.6% yield.
Watchpoints
No urgent risks highlighted.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1025.28
Analyst Target
$1003.15
Upside/Downside
-2.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LLY and closest competitors.
Updated 2025-11-14
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LLY
Eli Lilly and Company
Primary
|
+668.5% | +200.0% | +31.6% | +35.9% | +24.2% | +11.1% |
|
ABBV
AbbVie Inc.
Peer
|
+187.1% | +69.5% | +41.8% | +28.3% | +2.7% | +6.0% |
|
MRK
Merck & Co., Inc.
Peer
|
+42.2% | +2.0% | -2.0% | +24.6% | +10.5% | +7.7% |
|
ABT
Abbott Laboratories
Peer
|
+25.7% | +34.2% | +15.7% | -2.3% | +0.9% | +3.4% |
|
TMO
Thermo Fisher Scientific Inc.
Peer
|
+21.9% | +6.9% | +8.9% | +40.7% | +9.6% | +1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
50.26
Forward P/E
45.25
PEG Ratio
N/A
P/B Ratio
38.6
P/S Ratio
15.44
EV/Revenue
16.0
EV/EBITDA
33.09
Market Cap
$919.12B
Profitability
Profit margins and return metrics
Profit Margin
30.99%
Operating Margin
48.29%
Gross Margin
83.03%
ROE
96.47%
ROA
17.6%
Growth
Revenue and earnings growth rates
Revenue Growth
+53.9%
Earnings Growth
+480.4%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+475.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.79
High debt
Current Ratio
1.55
Good
Quick Ratio
0.72
Poor
Cash/Share
$11.07
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-05
$N/A
2025-10-30
$7.02
+19.1% surprise
2025-08-07
$6.29
+14.5% surprise
2025-05-01
$3.06
-25.6% surprise
Healthcare Sector Comparison
Comparing LLY against 23 companies in the Healthcare sector
(10 bullish, 13 neutral, 0 bearish)
P/E Ratio
50.26
This Stock
vs
37.07
Sector Avg
+35.6%
(Expensive)
Return on Equity (ROE)
96.47%
This Stock
vs
37.85%
Sector Avg
+154.9%
(Excellent)
Profit Margin
30.99%
This Stock
vs
13.56%
Sector Avg
+128.4%
(Superior)
Debt to Equity
1.79
This Stock
vs
1.21
Sector Avg
+48.1%
(Higher)
Revenue Growth
53.9%
This Stock
vs
11.02%
Sector Avg
+389.2%
(Fast Growth)
Current Ratio
1.55
This Stock
vs
1.95
Sector Avg
-20.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LLY
Eli Lilly and Company
|
BULLISH | $919.12B | 50.26 | 96.5% | 31.0% | $1025.28 | |
|
ABBV
AbbVie Inc.
|
NEUTRAL | $410.67B | 176.03 | 138.0% | 4.0% | $232.36 | |
|
MRK
Merck & Co., Inc.
|
BULLISH | $230.65B | 12.29 | 39.5% | 29.6% | $92.92 | |
|
ABT
Abbott Laboratories
|
NEUTRAL | $227.08B | 16.39 | 30.6% | 31.9% | $130.59 | |
|
TMO
Thermo Fisher Scientific Inc.
|
NEUTRAL | $217.96B | 33.45 | 13.1% | 15.0% | $578.71 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-13 | ZAKROWSKI DONALD A | Officer | Sale | 1,000 | $1,010,500 |
| 2025-11-12 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 305,000 | $308,411,204 |
| 2025-11-11 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 283,131 | $279,347,680 |
| 2025-11-10 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 16,869 | $16,405,396 |
| 2025-11-10 | SKOVRONSKY DANIEL | Officer | Gift | 179 | - |
| 2025-11-10 | RICKS DAVID A | Chief Executive Officer | Gift | 24,750 | - |
| 2025-11-05 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 179,042 | $167,092,104 |
| 2025-11-05 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 40,432 | $38,473,442 |
| 2025-11-04 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 526 | $479,038 |
| 2025-11-03 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 300,000 | $266,648,921 |
| 2025-10-31 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 301,342 | $260,165,031 |
| 2025-10-20 | SULZBERGER GABRIELLE | Director | Stock Award | 6 | $4,958 |
| 2025-10-20 | FYRWALD J. ERIK | Director | Stock Award | 12 | $9,917 |
| 2025-10-20 | LUCIANO JUAN R | Director | Stock Award | 18 | $14,833 |
| 2025-10-20 | ALVAREZ RALPH | Director | Stock Award | 14 | $11,750 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
27 analysts
Morgan Stanley
2025-11-13
Overweight
Overweight
Citigroup
2025-11-12
Buy
Buy
Freedom Capital Markets
2025-11-10
Buy
Hold
Leerink Partners
2025-11-10
Market Perform
Outperform
UBS
2025-11-07
Buy
Buy
BMO Capital
2025-11-06
Outperform
Outperform
Cantor Fitzgerald
2025-10-31
Overweight
Overweight
Guggenheim
2025-10-16
Buy
Buy
Guggenheim
2025-10-08
Buy
Buy
Morgan Stanley
2025-10-03
Overweight
Overweight